Driving Neurological Disorder Drugs Market Growth in 2025: The Role of Rising Neurological Disorders Drive Growth In Drugs Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Neurological Disorder Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size for drugs treating neurological disorders has seen robust growth in the previous years. From $84.6 billion in 2024, it is anticipated to reach $89.24 billion in 2025, showing a compound annual growth rate (CAGR) of 5.5%. This significant development over the historical period can be attributed to several factors including successful animal testing results, a rise in treatment therapies, increase in neurological issues, government interventions, and escalating healare spending.

How Will the Neurological Disorder Drugs Market Size Evolve and Grow by 2029?
The market for drugs treating neurological disorders is anticipated to experience robust growth in the coming years, expanding to "$110.99 billion in 2029 with a compound annual growth rate (CAGR) of 5.6%. This projected growth within the timeframe is due to several factors such as the development of personalized therapeutic options, an intensified focus on treatments that modify the course of disease, wider utilization of digital biomarker technology, and the rise in neurological disease incidence. Over this forecast period, the market is expected to be influenced by several key trends including the progression in drug development methodologies, advances in neuroimaging techniques, evolvement in genetic studies, strategic collaborations and licensing deals, along with the emergence of regenerative medicine.

View the full report here:
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

What Drivers Are Propelling the Growth of Neurological Disorder Drugs Market Forward?
The burgeoning incidence of neurological ailments is anticipated to drive the expansion of the neurological disorder drugs marketplace. Neurological complications, which refer to disorders impacting the brain, spinal cord, and nerves due to anatomical, biochemical, or electrical irregularities, result in various symptoms. The surge in such health conditions is ascribed to the aging global populace and amplified exposure to environmental, metabolic, and lifestyle risk determinants. Neurological disorder medications play a pivotal function in controlling these intricate conditions, offering symptom relief, decelerating disease advancement, and enhancing long-term patient results. For example, in September 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, forecasts that the dementia-afflicted population in the country would more than double from 2023 to 2058, rising from nearly 411,100 in 2023 to 849,300 in 2058, impacting roughly 315,500 men and 533,800 women. Consequently, the escalating prevalence of neurological disorders is stimulating the development of the neurological disorder drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Trends Will Shape the Neurological Disorder Drugs Market Through 2029 and Beyond?
In the neurological disorder drugs market, prominent companies are emphasizing the creation of inventive Ocrelizumab drug therapies. Their goal is to increase treatment effectiveness, improve patient results, and provide more treatment alternatives for those suffering from multiple sclerosis. Ocrelizumab, a humanized monoclonal antibody, is used therapeutically in treating multiple sclerosis, a form of neurological disorder. For instance, in February 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, introduced a new disease-modifying therapy (DMT) drug for multiple sclerosis, named Ocrevus (Ocrelizumab) in India. Ocrevus is the first and only DMT approved for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), and its approval was based on over a decade of clinical and real-world data. Further indicating its breakthrough, the drug targets CD20-positive B cells which are suspected to contribute to the autoimmune attack on the central nervous system in multiple sclerosis. Notably, it is the first drug approved to treat both RRMS and PPMS, with intravenous administration, typically every six months, and has been proven effective in minimizing disease activity and halting disability progression in clinical trials.

What Are the Key Segments in the Neurological Disorder Drugs Market?
The neurological disorder drugs market covered in this report is segmented -

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:
1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Who Are the Key Players Shaping the Neurological Disorder Drugs Market's Competitive Landscape?
Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

What Geographic Markets Are Powering Growth in the Neurological Disorder Drugs Market?
North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email:saumyas@tbrc.info
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.